IP Library Granted Patent US 8,536,166
Granted Patent B2
US 8,536,166 · App. 12/459,595 · Granted Sep 17, 2013

Inhibitors of Burton's tyrosine kinase

Inventors: Nolan James Dewdney (Saratoga, CA); Yan Lou (San Jose, CA); Eric Brian Sjogren (Mountain View, CA); Michael Soth (Milpitas, CA); Zachary Kevin Sweeney (Redwood City, CA)
Assignee: Roche Palo Alto LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,536,166
App. No.
12/459,595
Granted
Sep 17, 2013
Kind
B2
Abstract

This application discloses 5-phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-V: wherein, variables Q, R, Y 1 , Y 2 , Y 2′ , Y 3 , Y 4 , n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-V and at least one carrier, diluent or excipient.

Claims (212)

1. A compound of Formula I,

wherein:

R is H, —R 1 , —R 1 —R 2 —R 3 , —R 1 —R 3 , or —R 2 —R 3 ;

R 1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, and is optionally substituted with one or more R 1′ ;

each R 1′ is independently lower alkyl, hydroxy, lower hydroxyalkyl, lower alkoxy, halogen, nitro, amino, cycloalkyl, heterocycloalkyl, cyano, nitro, or lower haloalkyl;

R 2 is —C(═O), —C(═O)O, —C(═O)N(R 2′ ), —(CH 2 ) q , —O(CH 2 ) q , —(CH 2 ) q C(═O)O, —O(CH 2 ) q C(═O)N(R 2′ ), —CH 2 C(═O)N(R 2′ ), or —S(═O) 2 ;

R 2′ is H or lower alkyl;

q is 1, 2, or 3;

R 3 is H or R 4 ;

R 4 is lower alkyl, lower alkoxy, amino, aryl, arylalkyl, alkylaryl, heteroaryl, alkyl heteroaryl, heteroaryl alkyl, cycloalkyl, alkyl cycloalkyl, cycloalkyl alkyl, heterocycloalkyl, alkyl heterocycloalkyl, or heterocycloalkyl alkyl, and is optionally substituted with one or more lower alkyl, hydroxy, oxo, lower hydroxyalkyl, lower alkoxy, halogen, nitro, amino, cyano, lower alkylsulfonyl, or lower haloalkyl;

Q is CH or N;

Y 1 is H or lower alkyl;

Y 2 is Y 2a or Y 2b ;

Y 2a is H or halogen;

Y 2b is lower alkyl, optionally substituted with one or more Y 2b′ ;

Y 2b′ is hydroxy, lower alkoxy, or halogen;

each Y 2 ′ is independently Y 2′a or Y 2′b ;

y 2 ′a is halogen;

Y 2′b is lower alkyl, optionally substituted with one or more Y 2′b′ ;

Y 2b′ is hydroxy, lower alkoxy, or halogen;

n is 0, 1, 2, or 3;

Y 3 is halogen or lower alkyl, wherein the lower alkyl is optionally substituted with one or more substituents selected from the group consisting of hydroxy, lower alkoxy, amino, and halogen;

m is 0 or 1;

Y 4 is Y 4a , Y 4b , Y 4c , or Y 4d ;

Y 4a is H or halogen;

Y 4b is lower alkyl, optionally substituted with one or more substituents selected from the group consisting of lower haloalkyl, halogen, hydroxy, amino, cyano and lower alkoxy;

Y 4c is lower cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of lower alkyl, lower haloalkyl, halogen, hydroxy, amino, and lower alkoxy; and

Y 4d is amino, optionally susbstituted with one or more lower alkyl; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein Y 1 is methyl.

3. The compound of claim 2 , wherein n is 0, and m is 0.

4. The compound of claim 3 , wherein Y 2 is hydroxymethyl.

5. The compound of claim 4 , wherein Q is N.

6. The compound of claim 4 , wherein Q is CH.

7. The compound of claim 6 , wherein Y 4 is

wherein, Y 5 is H, halogen, lower alkyl, or lower haloalkyl.

8. The compound of claim 7 , wherein

R is —R 1 —R 2 —R 3 ;

R 1 is phenyl or pyridyl;

R 2 is —C(—O);

R 3 is R 4 ; and

R 4 is morpholine or piperazine, optionally substituted with one or more lower alkyl.

9. The compound of claim 7 , wherein

R is —R 1 —R 2 —R 3 ; and

R 1 is heteroaryl.

10. The compound of claim 7 , wherein

R is —R 1 —R 2 ; and

R 1 is heteroaryl.

11. The compound of claim 7 , wherein

R is —R 1 ; and

R 1 is heteroaryl.

12. The compound of claim 6 , wherein Y 4 is

wherein, Y 5 and Y 6 are independently H or lower alkyl.

13. The compound of claim 12 , wherein

R is —R 1 —R 2 —R 3 ;

R 1 is phenyl or pyridyl;

R 2 is —C(—O);

R 3 is R 4 ; and

R 4 is morpholine or piperazine, optionally substituted with one or more lower alkyl.

14. A compound of Formula II,

wherein:

R is H, —R 1 , —R 1 —R 2 —R 3 , —R 1 —R 3 , or —R 2 —R 3 ;

R 1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, and is optionally substituted with one or more R 1′ ;

each R 1′ is independently lower alkyl, hydroxy, lower hydroxyalkyl, lower alkoxy, halogen, nitro, amino, cycloalkyl, cycloalkyl lower alkyl, heterocycloalkyl, cyano, nitro, or lower haloalkyl;

R 2 is —C(—O), —C(—O)O, —C(—O)N(R 2′ ) 2 , —(CH 2 ) q , —O(CH 2 ) q , —CH 2 C(—O), —CH 2 C(—O)N(R 2′ ) 2 , or —S(—O) 2 ;

each R 2′ is independently H, lower alkyl, lower alkoxy, lower haloalkyl, or lower hydroxyalkyl;

q is 1, 2, or 3;

R 3 is H or R 4 ;

R 4 is lower alkyl, lower alkoxy, amino, aryl, arylalkyl, alkylaryl, heteroaryl, alkyl heteroaryl, heteroaryl alkyl, cycloalkyl, alkyl cycloalkyl, cycloalkyl alkyl, heterocycloalkyl, alkyl heterocycloalkyl, or heterocycloalkyl alkyl, and is optionally substituted with one or more lower alkyl, hydroxy, oxo, lower hydroxyalkyl, lower alkoxy, halogen, nitro, amino, cyano, lower alkylsulfonyl, or lower haloalkyl;

Q is CH 2 , CH(Y′) or NH;

Y′ is halogen, hydroxy, or lower alkyl, wherein the lower alkyl is optionally substituted with one or more substituents selected from the group consisting of hydroxy, lower alkoxy, amino, and halogen;

Y 1 is H or lower alkyl;

Y 2 is Y 2a or Y 2b ;

Y 2a H or halogen;

Y 2b is lower alkyl, optionally substituted with one or more Y 2b′ ;

Y 2b′ is hydroxy, lower alkoxy, or halogen;

each Y 2′ is independently Y 2′a or Y 2b′ ;

Y 2′a halogen;

Y 2′b is lower alkyl, optionally substituted with one or more Y 2′b′ ;

Y 2′b′ is hydroxy, lower alkoxy, or halogen;

n is 0, 1, 2, or 3;

Y 3 is halogen or lower alkyl, wherein the lower alkyl is optionally substituted with one or more substituents selected from the group consisting of hydroxy, lower alkoxy, amino, and halogen;

m is 0 or 1;

Y 4 is Y 4a , Y 4b , Y 4c , or Y 4d ;

Y 4a is H or halogen;

Y 4b is lower alkyl, optionally substituted with one or more substituents selected from the group consisting of lower haloalkyl, halogen, hydroxy, amino, cyano and lower alkoxy;

Y 4c is lower cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of lower alkyl, lower haloalkyl, halogen, hydroxy, amino, and lower alkoxy; and

Y 4d is amino, optionally susbstituted with one or more lower alkyl;

or a pharmaceutically acceptable salt thereof

15. The compound of claim 14 , wherein Y 1 is methyl.

16. The compound of claim 15 , wherein n is 0, and m is 0.

17. The compound of claim 16 , wherein Y 2 is hydroxymethyl.

18. The compound of claim 17 , wherein Q is NH.

19. The compound of claim 17 , wherein Q is CH 2 .

20. The compound of claim 19 , wherein Y 4 is

wherein, Y 5 is H, halogen, lower alkyl, or lower haloalkyl.

21. The compound of claim 20 , wherein

R is —R 1 —R 2 —R 3 ;

R 1 is phenyl or pyridyl;

R 2 is —C(—O);

R 3 is R 4 ; and

R 4 is morpholine or piperazine, optionally substituted with one or more lower alkyl.

22. The compound of claim 20 , wherein

R is R 1 ; and

R 1 is pyrazolyl, optionally substituted with R 1′ .

23. The compound of claim 14 , wherein Y 4 is

wherein, Y 5 and Y 6 are independently H or lower alkyl.

24. The compound of claim 20 , wherein

R is —R 1 —R 2 —R 3 ;

R 1 is phenyl or pyridyl;

R 2 is —C(—O);

R 3 is R 4 ; and

R 4 is morpholine or piperazine, optionally substituted with one or more lower alkyl.

25. The compound of claim 20 , wherein

R is R 1 ; and

R 1 is pyrazolyl, optionally substituted with R 1′ .

26. A compound selected from the group consisting of:

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(morpholine-4-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-2H-isoquinolin-1-one;

2-{3-[6-(2,2-Difluoro-benzo[1,3]dioxo1-5-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(4-(morpholine-4-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-{3-[6-(1-ethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-{2-hydroxymethyl-3-[4-methyl-6-(1-methyl-1H-pyrazol-4-ylamino)-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-N,N-dimethyl-benzamide;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-N,N-diethyl-benzamide;

6-Dimethylamino-2-(2-hydroxymethyl-3-{4-methyl-6[4-(morpholine-4-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-{2-hydroxymethyl-3-methyl-6-(4-morpholin-4-ylmethyl-phenylamino)-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-5-oxo-6-[4-(pyrrolidine-1-carbonyl)-phenylamino]-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-(1-Fluoro-cyclopropyl)-2-(2-hydroxymethyl-3-{4-methyl-6[ 4 -(morpholine-4-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{6-[4-(4hydroxy-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{6-[4-(4-methoxy-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[4-4-methyl-piperazine-1-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-N-(2-hydroxy-ethyl)-N-methyl-benzamide;

6-Cyclopropyl-2-[3-(6-{4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-phenylamino}-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl)-2-hydroxymethyl-phenyl]-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[4-(2,6-dimethyl-morpholine-4-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[4-(1,1-dioxo-1λ 6 -thiomorpholine-4-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[4-(4-ethoxy-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[4-(4-ethyl-piperazine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-6-(4-morpholin-4-ylmethyl-phenylamino)-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(3-{6-[4-(1,1-dioxo-1λ 6 -thiomorpholine-4-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-(3-{6-[4-(4-Acetyl-piperazine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-6-cyclopropyl-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-5-oxo-6-[4-(3-oxo-piperazine-1-carbonyl)-phenylamino]-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[4-(4,4-difluoro-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-(3-{6-[4-(4-Amino-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-6-cyclopropyl-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{6-[4-(4-hydroxy-4-methyl-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-N-(2-methoxy-ethyl)-N-methyl-benzamide;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino }-N-ethyl-N-methyl-benzamide;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{3-[6-(1-ethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(3-{6-[4-(4-ethyl-piperazine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-N,N-bis-(2-methoxy-ethyl)-benzamide;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino }-N-(2-methoxy-ethyl)-benzamide;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-N,N-bis-(2-hydroxy-ethyl)-benzamide;

6-tert-Butyl-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(morpholine-4-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(4-methyl-[1,4]diazepane-1-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3 -oxo-3 ,4-dihydro-pyrazin-2-ylamino }-N-ethyl-benzamide;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{6-[4-(4-isopropyl-piperazine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(3-{6-[4-(4-ethoxy-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(2-hydroxymethyl-3-{6-[4-(4-hydroxy-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{6-(4-methoxymethyl-piperidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{6-[1-(2-methoxy-ethyl)-1H-pyrazol-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-5-oxo-6-[1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-4-ylamino]-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-(4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino }-pyrazol-1-yl)-N,N-dimethyl-acetamide;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-5-oxo-6-(1H-pyrazol-3-ylamino)-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-5-oxo-6-[4-(piperazine-1-carbonyl)-phenylamino]-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-5-[4-(2-morpholin-4-yl-2-oxo-ethyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{6-[3-methoxy-4-(morpholine-4-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-y}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

7-{6-[3-(6-tert-Butyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-3,4-dihydro-1H-quinolin-2-one;

2-{3-[6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one;

7-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-3,4-dihydro-1H-quinolin-2-one;

7-{6-[3-(6-Dimethylamino-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-3,4-dihydro-1H-quinolin-2-one;

6-tent-Butyl-2-{3-[6-(1-ethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[4-((S)-3-ethoxy-pyrrolidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[4-((R)-3-ethoxy-pyrrolidine-1-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(2-hydroxymethyl-3-{4-methyl-5-oxo-6-[4-(piperazine-1-carbonyl)-phenylamino]-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-{2-hydroxymethyl-3-[6-(1-isopropyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(morpholine-4-carbonyl)-3-nitro-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-(4-{6-[3-(6-Dimethylamino-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-pyrazol-1-yl)-N,N-dimethyl-acetamide;

6-Cyclopropyl-2-(3-{6-[3-fluoro-4-(morpholine-4-carbonyl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{3-[6-(3-fluoro-4-morpholin-4-yl-phenylamino)-4-methyl-5-oxo-4,5-dihydro -pyrazin-2-yl]-2-hydroxymethyl-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

2-[3-(6-{4-[Bis-(2-hydroxy-ethyl)-amino]-phenylamino }-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl)-2-hydroxymethyl-phenyl]-6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-5-oxo-6-(4-piperidin-1-ylmethyl-phenylamino)-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[1-(2-morpholin-4-yl-2-oxo-ethyl)-1H-pyrazol-4-ylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3 ,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-{3-[6-(1-cyclopropylmethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(3-{6-[4-(2-hydroxy-ethoxy)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-(Ethyl-methyl-amino)-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(morpholine-4-carbonyl) -phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[1-(2,2-difluoro-ethyl)-1H-pyrazol-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-(4-{6-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-pyrazol-1-yl)-N-methyl-acetamide;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-5-oxo-6-(1-propyl-1H-pyrazol-4-ylamino)-4,5 -dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

2-{3-[6-(1-Cyclobutylmethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-{2-hydroxymethyl-3-[4-methyl-5-oxo-6-(1-propyl-1H-pyrazol-4-ylamino)-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-6-(4-morpholin-4-yl-phenylamino)-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

2-{3-[6-(3,4-Dihydro-2H-benzo [1,4]oxazin-6-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one;

6-Cyclopropyl-2-(3-{6-[1-(2-hydroxy-ethyl)-1H-pyrazol-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-6-(2-morpholin-4-yl-pyridin-4-ylamino)-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

6-tent-Butyl-2-{2-hydroxymethyl-3-[4-methyl-6-(2-morpholin-4-yl-pyridin-4-ylamino)-5-oxo-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

2-{3-[6-(1-Ethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-6-(1-hydroxy-1-methyl-ethyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(2-hydroxymethyl-3-{4-methyl-6-[6-(4-methyl-piperazin-1-yl)-pyridin-3-ylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-{2-hydroxymethyl-3-[4-methyl-5-oxo-6-(1,2,3,4-tetrahydro-isoquinolin-7-ylamino)-4,5-dihydro-pyrazin-2-yl]-phenyl}-3,4-dihydro-2H-isoquinolin-1-one;

2-(3-{6-[1-(2,2-Difluoro-ethyl)-1H-pyrazo1-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-6-(1-hydroxy-1-methyl-ethyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-(3-{6-[1-(2,2-Difluoro-ethyl)-1H-pyrazo1-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(3-{6-[4-(2-dimethylamino-ethoxy)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-[2-(3-{6-[1-(2,2-Difluoro-ethyl)-1H-pyrazol-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinolin-6-yl]-2-methyl-propionitrile;

6-Dimethylamino-2-(2-hydroxymethyl-3-{6-[1-(2-hydroxy-propyl)-1H-pyrazol-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(3-{6-[4-(1,4-dimethyl-3-oxo-piperazin-2-yl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-3,4-dihydro-2H-isoquinolin-1-one;

2-(3-{6-[1-(2,3-Dihydroxy-propyl)-1H-pyrazol-4-ylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-hydroxymethyl-phenyl)-6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one;

6-Dimethylamino-2-(2-hydroxymethyl-3-{4-methyl-6-[4-(morpholine-4-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-2H-isoquinolin-1-one;

6-Cyclopropyl-2-{3-[6-(1-ethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-2-hydroxymethyl-phenyl}-2H-isoquinolin-1-one;

2-(4-{6-[3-(6-Dimethylamino-1-oxo-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-phenoxy)-N-methyl-acetamide;

(4-{6-[3-(6-Cyclopropyl-1-oxo-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-4-methyl-3-oxo-3,4-dihydro-pyrazin-2-ylamino}-pyrazol-1-yl)-acetic acid; and

6-Cyclopropyl-2-(2-hydroxymethyl-3-{4-methyl-6-[1-(1-methyl-1H-imidazol-2-ylmethyl)-1H-pyrazol-4-ylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-2H-isoquinolin-1-one.

27. A pharmaceutical composition comprising the Btk inhibitor compound of claim 14 , admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2009
From: DEWDNEY, NOLAN JAMES; LOU, YAN; SJOGREN, ERIC BRIAN; SOTH, MICHAEL; SWEENEY, ZACHARY KEVIN
To: ROCHE PALO ALTO LLC
Reel/Frame 023117/0959 →
Continuity (2)
Provisional Application 61077510 · Jul 2, 2008
Related Publication 20100004231A1 · Jan 7, 2010